Table 2.
Prior anticancer therapy and surgery.
| Prior therapy, n (%) | Cohort 1 N = 26 | Cohort 2 N = 28 |
|---|---|---|
| Surgery | 18 (69.2) | 25 (89.3) |
| Radiotherapy | 14 (53.8) | 18 (64.3) |
| Systemic therapy | 13 (50.0) | 28 (100.0) |
| Neoadjuvant | 1 (3.8) | 7 (25.0) |
| Adjuvant | 13 (50.0) | 20 (71.4) |
| Locally advanced/metastatic | 1 (3.8) | 28 (100) |
| Chemotherapy | 27 (96.4)b | |
| Endocrine therapy | 1 (3.8)a | 25 (89.3) |
| Targeted therapy | 8 (28.6) | |
| Other | 7 (25.0) | |
| Median line of systemic therapy for metastatic disease (range) | — | 3 (1–7) |
| Prior lines of chemotherapy for metastatic disease | ||
| 1 | — | 15 (53.6) |
| 2 | — | 12 (42.9) |
| Prior lines of endocrine therapy for metastatic disease | ||
| 1 | 1 (3.8)a | 10 (35.7) |
| 2 | — | 7 (25.0) |
| ≥3 | — | 8 (28.6) |
N number of patients treated, n number of patients in category.
aOne patient in cohort 1 previously received 8 days of NSAI in MBC setting.
bOne patient in cohort 2 did not receive chemotherapy for metastatic disease but did receive a target therapy (alpelisib).